Call to Action on Childhood TB

Notice from the Stop TB Partnership:

We are writing to encourage you to sign the Call to Action on Childhood TB.

The call was an outcome of an international meeting organized jointly by the European Centre for Disease Prevention and Control (ECDC) and the Stop TB Partnership’s Childhood TB Subgroup in March.

The meeting was attended by a wide range of participants, including researchers, paediatricians, community representatives, civil society organizations, and ECDC and WHO staff. The objectives of the meeting were to:

  • identify and highlight the gaps, challenges and needs in childhood TB control.
  • prepare the scientific rationale for the need for advocacy and to identify the key areas where more advocacy and targeted engagement with stakeholders are needed.
  • reach a consensus on how to advocate for childhood TB control.

There was strong consensus among participants on the urgent need to make the voice of children heard through concerted advocacy efforts. A detailed programme of the meeting, with all presentations, can be found at the ECDC website

The Call to Action is now available on the Stop TB Partnership website. Click here to sign.

Photo by John-Michael Maas

Learn more about childhood TB

Links to previous coverage of childhood TB by the WGND

WHO Releases Factsheet on Children and TB

MSF Podcast: Difficulties of Treating Children with TB

Interview with Dr. Anneke Hesseling: Part One, Part Two, and Part Three

TB R&D Weekly Update: Combined Isoniazid and Antiretroviral Therapy Protects HIV-infected Children

Interview with Mark Cotton: Part One and Part Two

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...